Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence

Impact of a real-time diagnostic and antimicrobial stewardship workflow on time to appropriate therapy for infections caused by multidrug-resistant Gram-negative organisms

(2023) Katie A. McCrink et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Rapid selection of a cefiderocol-resistant Escherichia coli producing NDM-5 associated with a single amino acid substitution in the CirA siderophore receptor

(2023) Agnès B Jousset et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Performance evaluation of the UMIC® Cefiderocol to determine MIC in Gram-negative bacteria

(2023) Laurent Dortet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetics of cefiderocol during extracorporeal membrane oxygenation: A case report

(2023) Jordi Riera et al.   PERFUSION-UK

Comparison of Broth Microdilution, Disk Diffusion and Strip Test Methods for Cefiderocol Antimicrobial Susceptibility Testing on KPC-Producing Klebsiella pneumoniae

(2023) Federica Bovo et al.   Antibiotics-Basel

Disc Diffusion and ComASP® Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine

(2023) Gabriele Bianco et al.   Antibiotics-Basel

Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series

(2023) Ángel Marcos Fendian et al.   Infectious Diseases and Therapy

Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials

(2023) Mohamed Aziz Daghmouri et al.   EClinicalMedicine

Cefiderocol for the Treatment of Infections Due To Metallo-Beta-Lactamase-Producing Pathogens in the CREDIBLE-CR And APEKS-NP Phase 3 Randomized Studies

(2022) Jean-Francois Timsit et al.   CLINICAL INFECTIOUS DISEASES

Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study

(2022) Eric P. Skaar et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials

(2022) Patrice Nordmann et al.   Microbial Drug Resistance

Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies

(2022) David L. Paterson et al.   Infectious Diseases and Therapy

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

(2022) Marco Falcone et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

(2022) Pranita D. Tamma et al.   CLINICAL INFECTIOUS DISEASES

Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales

(2022) Rémy A. Bonnin et al.   CLINICAL MICROBIOLOGY AND INFECTION

Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial

(2022) Adrien Bouglé et al.   INTENSIVE CARE MEDICINE

Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing

(2022) Erika Matuschek et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program

(2022) Dee Shortridge et al.   Microbiology Spectrum

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance

(2022) Stamatis Karakonstantis et al.   Antibiotics-Basel

Evolution and transmission of cefiderocol-resistant Acinetobacter baumannii during an outbreak in the burn intensive care unit

(2022) Steven M Smoke et al.   CLINICAL INFECTIOUS DISEASES

Cefiderocol Dosing for Patients Receiving Continuous Renal Replacement Therapy

(2022) Xiaohui Wei et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Widespread emergence of OmpK36 loop 3 insertions among multidrug-resistant clones of Klebsiella pneumoniae

(2022) Sophia David et al.   PLoS Pathogens

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019

(2022) James A. Karlowsky et al.   Microbiology Spectrum

Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials

(2022) Christopher Longshaw et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022

(2022) Marco Coppi et al.   Eurosurveillance

Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections

(2022) Victoria Gavaghan et al.   INFECTION

Pharmacokinetic Analysis and In Vitro Synergy Evaluation of Cefiderocol, Sulbactam, and Tigecycline in an Extensively Drug-Resistant Acinetobacter baumannii Pneumonia Patient Receiving Continuous Venovenous Hemodiafiltration

(2022) Emir Kobic et al.   Open Forum Infectious Diseases

Performance of discs, sensititre EUMDROXF microplates and MTS gradient strips for the determination of the susceptibility of multidrug-resistant Pseudomonas aeruginosa to cefiderocol

(2022) Léa Devoos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case series

(2022) Baptiste Hoellinger et al.   CLINICAL MICROBIOLOGY AND INFECTION

600. Cefiderocol is Not Sequestered in an Ex vivo Extracorporeal Membrane Oxygenation (ECMO) Circuit

(2022) Angela V Berry et al.   Open Forum Infectious Diseases

Pharmacokinetic of Cefiderocol in Critically Ill Patients Receiving Renal Replacement Therapy: A Case Series

(2022) Simone Mornese Pinna et al.   Antibiotics-Basel

Successful Treatment of Aortic Endocarditis by Achromobacter xylosoxidans with Cefiderocol Combination Therapy in a Non-Hodgkin Lymphoma Patient: Case Report and Literature Review

(2022) Gianfranco La Bella et al.   Antibiotics-Basel

Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study

(2021) Alexandre Bleibtreu et al.   Microorganisms

Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii

(2021) Laurent Poirel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Extensively drug-resistant Acinetobacter baumannii nosocomial pneumonia successfully treated with a novel antibiotic combination

(2021) Noor Zaidan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii

(2021) Jacinda C. Abdul-Mutakabbir et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA

(2021) Sabrina Klein et al.   CLINICAL INFECTIOUS DISEASES

An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of IVACs caused by Enterobacterales in critically ill adult patients

(2021) Milo Gatti et al.   Expert Review of Anti-Infective Therapy

Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia

(2021) Takayuki Katsube et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Treatment of Patients with Serious Infections Due to Carbapenem‐resistant Acinetobacter baumannii : How Viable are the Current Options?

(2021) J Nicholas O’Donnell et al.   PHARMACOTHERAPY

Successful prolonged cefiderocol treatment of a chronic left pleural empyema caused by Pseudomonas aeruginosa in a patient affected by COVID-19: a case report

(2021) Luca Borghesi et al.   Journal of Global Antimicrobial Resistance

An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients

(2021) Milo Gatti et al.   Infection and Drug Resistance

Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration

(2021) Emir Kobic et al.   Open Forum Infectious Diseases

Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives

(2021) Davide Fiore Bavaro et al.   Antibiotics-Basel

Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance

(2021) Christina König et al.   Antibiotics-Basel

In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019

(2021) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions

(2021) Matteo Bassetti et al.   ARCHIVES OF MEDICAL RESEARCH

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections

(2021) Pranita D Tamma et al.   CLINICAL INFECTIOUS DISEASES

Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression

(2021) Patricia J Simner et al.   CLINICAL INFECTIOUS DISEASES

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

(2021) Mical Paul et al.   CLINICAL MICROBIOLOGY AND INFECTION

Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy

(2021) Eric Wenzler et al.   CLINICAL PHARMACOKINETICS

All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies

(2021) Thomas P. Lodise et al.   Expert Review of Anti-Infective Therapy

Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Pneumonia Patients and Healthy Subjects

(2021) Nao Kawaguchi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales

(2021) Patricia J. Simner et al.   Microbial Drug Resistance

Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial

(2021) Hugh Wright et al.   Trials

A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol

(2021) Milo Gatti et al.   Journal of Global Antimicrobial Resistance

1058. In Vitro and In Vivo Antibacterial Activity of Cefiderocol against Burkholderia spp

(2021) Merime Oota et al.   Open Forum Infectious Diseases

1066. In Vitro and in Vivo Antimicrobial Activity of Cefiderocol and Comparators against Achromobacter spp

(2021) Ryuichiro Nakai et al.   Open Forum Infectious Diseases

In Vitro Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA

(2021) Christi L. McElheny et al.   Microbiology Spectrum

Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy

(2021) Emanuele Rando et al.   Antibiotics-Basel

An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients

(2021) Milo Gatti et al.   Antibiotics-Basel

Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan

(2021) Yoshinori Yamano et al.   Journal of Global Antimicrobial Resistance

In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units

(2020) Alyssa R. Golden et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

(2020) Mohd H. Abdul-Aziz et al.   INTENSIVE CARE MEDICINE

Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017

(2020) Jean-Louis Vincent et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cefiderocol for extensively-drug resistant gram-negative bacterial infections: real-world experience from a case-series and review of the literature

(2020) Sandra Zingg et al.   Open Forum Infectious Diseases

Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan‐drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient

(2020) Andrew B. Gainey et al.   PEDIATRIC PULMONOLOGY

Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-Negative infections in ICU patients

(2020) Marco Falcone et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

(2020) Matteo Bassetti et al.   LANCET INFECTIOUS DISEASES

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

(2020) Richard G Wunderink et al.   LANCET INFECTIOUS DISEASES

Compassionate use of cefiderocol in a pancreatic abscess and emergence of resistance

(2020) C. Grande Perez et al.   MEDECINE ET MALADIES INFECTIEUSES

Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively- and pan-resistant Acinetobacter baumannii

(2020) A. Oliva et al.   Journal of Global Antimicrobial Resistance

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection

(2020) Nao Kawaguchi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives

(2020) Marios Karvouniaris et al.   Expert Review of Anti-Infective Therapy

Metabolism, Excretion, and Pharmacokinetics of [14 C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration

(2019) Shiro Miyazaki et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Reproducibility of broth microdilution MICs for the novel Siderophore cephalosporin, Cefiderocol, determined using Iron-depleted cation-adjusted Mueller-Hinton broth

(2019) Meredith A. Hackel et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects

(2019) Takayuki Katsube et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antimicrobial Resistance or Delayed Appropriate Therapy—Does One Influence Outcomes More Than the Other among Patients with Serious Infections due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae?

(2019) Thomas Lodise et al.   Open Forum Infectious Diseases

In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models

(2019) Rio Nakamura et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report

(2019) Enrico Maria Trecarichi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Co-Infections of Two Strains of NDM-1 and OXA-232 Co-producing Klebsiella pneumoniae in a Kidney Transplant Patient

(2019) Deisy A. Contreras et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects

(2019) Carlos Sanabria et al.   CLINICAL THERAPEUTICS

An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria

(2019) Catia Cillóniz et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Compassionate use of cefiderocol in the treatment of an intraabdominal infection due to multidrug resistant Pseudomonas aeruginosa : A case report

(2019) Ryan W. Stevens et al.   PHARMACOTHERAPY

Difficult-to-Treat Antibiotic-Resistant Gram-Negative Pathogens in the Intensive Care Unit: Epidemiology, Outcomes, and Treatment

(2019) Jeffrey R. Strich et al.   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin

(2019) Takafumi Sato et al.   CLINICAL INFECTIOUS DISEASES

Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study

(2019) Matteo Bassetti et al.   Infection and Drug Resistance

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects

(2018) Yutaka Saisho et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OUP accepted manuscript

(2018)   CLINICAL INFECTIOUS DISEASES

Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters

(2018) Takayuki Katsube et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship

(2018) Toshiaki Aoki et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model

(2018) Islam M. Ghazi et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

(2018) Evelina Tacconelli et al.   LANCET INFECTIOUS DISEASES

Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa

(2018) Islam M. Ghazi et al.   PHARMACOLOGY

Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria

(2018) Matteo Bassetti et al.   Current Opinion in Critical Care

Efficacy of Humanized Cefiderocol Exposures Over 72 hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model

(2018) Sean M Stainton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

(2018) Jonathan D Edgeworth et al.   CLINICAL INFECTIOUS DISEASES

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

(2018) Simon Portsmouth et al.   LANCET INFECTIOUS DISEASES

Impact of Delayed Appropriate Antibiotic Therapy on Patient Outcomes by Antibiotic Resistance Status From Serious Gram-negative Bacterial Infections

(2018) Nicole Gidaya Bonine et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance

(2017) Laia Fernández-Barat et al.   JOURNAL OF INFECTION

Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa

(2017) Bin Cai et al.   Open Forum Infectious Diseases

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity againstPseudomonas aeruginosa

(2016) Akinobu Ito et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

(2016) Tsukasa Ito-Horiyama et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function

(2016) Takayuki Katsube et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment

(2016) Takayuki Katsube et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Validation of Predictors of Adverse Outcomes in Hospital-Acquired Pneumonia in the ICU*

(2013) Mariano Esperatti et al.   CRITICAL CARE MEDICINE